reports
- Alexander Aukner
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd An...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7:45 AM EDT (1:45 PM CEST) on September 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a co...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Se...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapyRegulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patientsiRina-S continues to be ev...
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Mer...
Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Luxembourg, August 14, 2025 – Millicom (Tigo) today announced a key agreement with Empresas Públicas de Medellín (EPM) that advances its acquisition strategy in Colombia and unlocks a path toward the integration of Tigo-UNE and Colombia Telecomunicaciones (ColTel). Under the terms of the agreement: Millicom has committed to present an offer in EPM’s Law 226 sale process, subject to the terms published b...
- ABGSC Shipping & Transport Research
- Martin Mauseth
- Oliver Dunvold
- Petter Haugen
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million....
- ABGSC Shipping & Transport Research
- Martin Mauseth
- Oliver Dunvold
- Petter Haugen
Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025 August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcori...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
Millicom (Tigo) Q2 2025 Earnings Release
Millicom (Tigo) Q2 2025 Earnings Release Millicom (Tigo) Q2 2025 Earnings Release Luxembourg, August 7, 2025 – is pleased to announce its second quarter 2025 results. Please find below links to the Q2 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q2 2025 Highlights* Revenue $1.37 billion Operating profit $357 million, and record Adjusted EBITDA $641 million Net profit $676 million, including approximately $590 million net profit from infrastructure transactions Equity free cash flow $218 million Leverage of 2.18x, benefiting from one-time c...
Millicom (Tigo) declares $2.50 per share interim dividend to be paid i...
Millicom (Tigo) declares $2.50 per share interim dividend to be paid in two equal installments on October 15, 2025 and April 15, 2026 Luxembourg, August 6, 2025 – In line with the press release published on June 13, 2025, the Board of Directors of Millicom International Cellular S.A. (“Millicom”) approved the interim dividend of $2.50 per share, to be paid in two equal installments of $1.25 per share on October 15, 2025 and April 15, 2026. Other important dates and information relating to the Interim Dividend are as follows: First Installment Interim Dividend Payment First Installment Int...
- ABGSC Shipping & Transport Research
- Martin Mauseth
- Oliver Dunvold
- Petter Haugen
- ABGSC Shipping & Transport Research
- Martin Mauseth
- Oliver Dunvold
- Petter Haugen
Millicom (Tigo) notice of second quarter 2025 results and video confer...
Millicom (Tigo) notice of second quarter 2025 results and video conference Millicom (Tigo) notice of second quarter 2025 results and video conference Luxembourg, July 17, 2025 – Millicom expects to announce its second quarter 2025 results on August 7, 2025, via a press release. Millicom is planning to host a video conference for the global financial community on August 7, 2025, at 14:00 pm (Stockholm) / 13:00 (London) / 08:00 (Miami). Registration for the interactive event is required at the following . After registering, you will receive a confirmation email containin...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quart...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,5...
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.